Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder

被引:117
作者
Veldic, Marin [1 ]
Kadriu, Bashkim [1 ]
Maloku, Ekrem [1 ]
Agis-Balboa, Roberto C. [1 ]
Guidotti, Alessandro [1 ]
Davis, John M. [1 ]
Costa, Erminio [1 ]
机构
[1] Univ Illinois, Coll Med, Inst Psychiat, Dept Psychiat, Chicago, IL 60612 USA
关键词
schizophrenia; bipolar disorder; epigenetics; reelin; glutamic acid decarboxylase; DNA-methyltransferase; 1;
D O I
10.1016/j.schres.2006.11.029
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
In the cerebral prefrontal cortex (PFC), DNA-methyltransferase 1 (DNMT1), the enzyme that catalyzes the methylation of cytosine at carbon atoms in position 5 in CpG dinucleotides, is expressed selectively in GABAergic neurons and is upregulated in layers I and II of schizophrenia (SZ) and bipolar disorder patients with psychosis (BDP). To replicate these earlier findings and to verify whether overexpression of DNMT1 and the consequent epigenetic decrease of reelin and glutamic acid decarboxylase (GAD) 67 mRNA expression also occur in GABAergic medium spiny neurons of the caudate nucleus (CN) and putamen (PT) of SZ and BDP, we studied the entire McLean 66 Cohort (Harvard Brain Tissue Resource Center, McLean Hospital, Belmont, MA) including SZ and BDP, which were matched with nonpsychiatric subjects. The data demonstrate that in GABAergic medium spiny neurons of CN and PT, unlike in GABAergic neurons of layer I and II PFC, the increased expression of DNMT1 and the decrease of reelin and GAD67 occur in SZ but not in BDP. This suggests that different epigenetic mechanisms must exist in the pathogenesis underlying SZ and BDP and implies that these disorders might involve two separate entities that are characterized by a well-defined neuropathology. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:51 / 61
页数:11
相关论文
共 56 条
[1]   Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients:: A preliminary report [J].
Abdolmaleky, HM ;
Cheng, KH ;
Russo, A ;
Smith, CL ;
Faraone, SV ;
Wilcox, M ;
Shafa, R ;
Glatt, SJ ;
Nguyen, G ;
Ponte, JF ;
Thiagalingam, S ;
Tsuang, MT .
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2005, 134B (01) :60-66
[2]   GENE-EXPRESSION FOR GLUTAMIC-ACID DECARBOXYLASE IS REDUCED WITHOUT LOSS OF NEURONS IN PREFRONTAL CORTEX OF SCHIZOPHRENICS [J].
AKBARIAN, S ;
KIM, JJ ;
POTKIN, SG ;
HAGMAN, JO ;
TAFAZZOLI, A ;
BUNNEY, WE ;
JONES, EG .
ARCHIVES OF GENERAL PSYCHIATRY, 1995, 52 (04) :258-266
[3]   Strange feelings: Do amygdala abnormalities dysregulate the emotional brain in schizophrenia? [J].
Aleman, A ;
Kahn, RS .
PROGRESS IN NEUROBIOLOGY, 2005, 77 (05) :283-298
[4]   PROJECTIONS FROM THE AMYGDALA TO BASOVENTRAL AND MEDIODORSAL PREFRONTAL REGIONS IN THE RHESUS-MONKEY [J].
BARBAS, H ;
DEOLMOS, J .
JOURNAL OF COMPARATIVE NEUROLOGY, 1990, 300 (04) :549-571
[5]   Modulation of synaptic plasticity and memory by Reelin involves differential splicing of the lipoprotein receptor Apoer2 [J].
Beffert, U ;
Weeber, EJ ;
Durudas, A ;
Qiu, SF ;
Masiulis, I ;
Sweatt, JD ;
Li, WP ;
Adelmann, G ;
Frotscher, M ;
Hammer, RE ;
Herz, J .
NEURON, 2005, 47 (04) :567-579
[6]   GABAergic interneurons: Implications for understanding schizophrenia and bipolar disorder [J].
Benes, FM ;
Berretta, S .
NEUROPSYCHOPHARMACOLOGY, 2001, 25 (01) :1-27
[7]   The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia [J].
Benes, FM ;
Matzilevich, D ;
Burke, RE ;
Walsh, J .
MOLECULAR PSYCHIATRY, 2006, 11 (03) :241-251
[8]  
BENES FM, 1992, J NEUROSCI, V12, P924
[9]   DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy [J].
Brueckner, B ;
Lyko, F .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (11) :551-554
[10]   Enhanced dizocilpine efficacy in heterozygous reeler mice relates to GABA turnover downregulation [J].
Carboni, G ;
Tueting, P ;
Tremolizzo, L ;
Sugaya, I ;
Davis, J ;
Costa, E ;
Guidotti, A .
NEUROPHARMACOLOGY, 2004, 46 (08) :1070-1081